BOSTON SCIENTIFIC CORP (BSX) Overview
Healthcare • NYSE • CIK 0000885725
Loading...
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Market Cap
$64.10B
P/E (TTM)
18.3x
Rev Growth (TTM)
+8.9%
Net Margin (TTM)
16.6%
FCF Yield (TTM)
5.2%
FCF Margin (TTM)
15.8%
Figures as of September 30, 2026
Filings
Primary-source SEC disclosures, read end-to-end. SEC figures cite the filing they come from.
10-Q2026 Q32026-11-02source
8-KEarnings2026-10-28source
8-KOct 20262026-10-07source
8-KSep 20262026-09-23source
8-KSep 20262026-09-08source
What your agent reads
Investor Relations
Company-published material — management’s own words, not SEC-audited. Each source below is labeled so your agent knows what to verify.
Company-published, not SEC-audited
Earnings
Q3
19 days ago
8-K releaseRevenue
$5.14B
+1.4%
Net Income
$582.00M
-22.9%
EPS
$0.40
-21.6%
Most recent quarterly earnings snapshot
Cash Flow Health
Free Cash Flow8/8 positive
TTM$3.3B
Q3 '26
$868.0M-32%
Q2 '26
$1.3B+648%
FCF Margin
TTM15.8%
Q3 '2616.9%-28%
Sector: 3.0%Top 25%
OCF Margin
20.1%
OCF/NI1.21x
CapEx Coverage
4.7x
FCF Yield5.2%
FCF Growth (3Y)+25%
Cash Conversion Cycle
109 days
DSO: –+DIO: 174−DPO: 65
Cash flow trends & capital efficiency
Capital Allocation
Total Shareholder Yield
TTM0.0%
Dividend & Payout Metrics
Dividend Yield (TTM)—
Free Cash Flow (TTM)$3.3B
Capital Return / FCF0.0%
Shares Outstanding (YoY)-2.2%↓ Buyback
Buyback data not disclosed in this company's filings.
Shows how management rewards shareholders
Valuation Metrics
Price-to-EarningsTTM
18.3x
Volatile
8Q: 48.9x-4187%
Valuation Lenses
Earnings
18.3x
vs – sector
Cash Flow
22.6x
EV/FCF vs –
Growth-Adj
0.7xPEG
Undervalued for growth
Quality-Adj
1.8P/E per %ROIC
ROIC: 10.3%
Shareholder Returns
Dividend
–
Buyback
–
Total Yield
–
Market Cap$64.10B
EV$75.45B
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Multi-angle valuation analysis with sector context
Margins & Efficiency
ROIC 75th pctile
Profitability Cascade
Gross
69.1%
Operating
18.7%
Top 25% in sector
Net
16.6%
Margins Unknown
Return on Invested CapitalTTM
10.3%
Stable
+0.0% YoY8Q: 9.1%+1.3%
P25MedianP75
75th pctl (med: -6.9%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
17.8%
8Q: 15.7%
Asset Turnover
0.48x
8Q: 0.48x
Leverage (1+D/E)
1.47x
D/E: 0.47x
DuPont: 12.4% ≈ 10.3% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
5.20x
8Q:5.49x
-77.7%
Invested Cap Turn
0.64x
8Q:0.64x
Flat
CapEx Intensity
2.7%
8Q:2.3%
CapEx/Depreciation
0.63x
FCF vs Net Margin Gap-0.8 pts
Margin trends, ROIC, and capital efficiency
Balance Sheet & Solvency
ND/EBITDA 2.0x
Net Debt / EBITDA
2.0xNet Debt: $11.34B
Interest Coverage
10.5x
+Strong interest coverage: 10.5x
Leverage Metrics
Debt-to-Equity
0.47x
Balance sheet risk & solvency analysis
Related Research
2 related posts